Industry / innovation partners

ALS Immunotherapy Moves Into the Extension Phase

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

GIST Care Looks Beyond First-Generation KIT Control

Pancreatic Cancer Finally Gets a RAS Moment

A Rare Pain Disorder Gets a Pivotal Trial

What happens when surgeons no longer need to be in the same country as their patients?

EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption

GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
